Last updated: May 14, 2023
Sponsor: University of Athens
Overall Status: Active - Recruiting
Phase
N/A
Condition
Warts
Rash
Rosacea
Treatment
Placebo
Food supplement Endocalyx
Clinical Study ID
NCT05184699
672/2-12-2021
Ages 18-75 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Caucasian patients with psoriatic disease (plaque-type psoriasis or psoriaticarthritis)
- Body mass index ≥18.5 Kg/m2
- If female, patients must be non-pregnant and non-breastfeeding
Exclusion
Exclusion Criteria:
- History of acute coronary syndrome. Coronary artery disease will be excluded by aclinical history, examination and electrocardiogram.
- Moderate or severe valve disease
- Primary cardiomyopathies
- Chronic obstructive pulmonary disease
- Asthma
- Chronic kidney disease
- Liver failure
- Malignancies
Study Design
Total Participants: 60
Treatment Group(s): 2
Primary Treatment: Placebo
Phase:
Study Start date:
November 01, 2022
Estimated Completion Date:
January 30, 2024
Study Description
Connect with a study center
Attikon University Hospital
Athens, Attiki 12462
GreeceActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.